Anika Therapeutics, Inc.

Listed Company

ANIKCIK 0000898437NasdaqAcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$112.82M

Net Income

$-10.88M

Total Assets

$190.27M

Equity

$143.47M

Shares Out

13.31M

Op. Cash Flow

$11.19M

ANIK$15.27+35.73% · past yearDBEQ Basic

Daily closing prices

Business

Anika Therapeutics develops and commercializes hyaluronic acid-based medical devices for osteoarthritis pain management and orthopedic regenerative medicine. Its OA Pain Management portfolio includes Monovisc and Orthovisc (licensed to Johnson & Johnson MedTech in the U.S.) and Cingal. Regenerative Solutions products include Integrity, Hyalofast, and Tactoset for cartilage and bone repair. Anika manufactures at its Bedford facility and distributes through exclusive U.S. licensing partnerships, direct sales channels, and international distributors.

Summary from 10-K filed 2026-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	113	120	121	114	148
Cost of revenue	49	44	38	41	65
Gross profit	64	76	83	73	83
Research & development	26	26	22	18	27
Selling, general & administrative	49	56	60	51	74
Total operating expenses	75	81	82	70	80
(Loss) income from operations	−11	−5	844,000	4	3
Interest and other income, net	2	2	2	654,000	−188,000
(Loss) income before income taxes	−9	−3	3	4	2
Provision for income taxes	672,000	6	7	2	−2
Loss from continuing operations	−10	−9	−3	2	—
Loss from discontinued operations, net of tax	−901,000	−48	−79	−17	—
Net loss	−11	−56	−83	−15	4
Continuing operations (in dollars per share)	−0.7	−0.6	−0.23	0.15	—
Discontinued operations (in dollars per share)	−0.06	−3.23	−5.41	−1.17	—
Earnings Per Share, Basic	−0.76	−3.83	−5.64	−1.02	0.29
Continuing operations (in dollars per share)	−0.7	−0.6	−0.23	0.15	—
Discontinued operations (in dollars per share)	−0.06	−3.23	−5.41	−1.17	—
Earnings Per Share, Diluted	−0.76	−3.83	−5.64	−1.02	0.28
Basic (in shares)	14	15	15	15	14
Diluted (in shares)	14	15	15	15	15
Foreign currency translation adjustment	2	−840,000	500,000	−725,000	−1
Comprehensive loss	−9	−57	−82	−16	3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	57	56	69	86	94
Accounts receivable, net	24	24	26	35	30
Inventories	19	24	24	40	36
Prepaid expenses and other current assets	3	5	7	9	8
Current assets held for sale	0	5	36	—	—
Total current assets	103	114	163	170	169
Property and equipment, net	40	39	37	48	48
Right-of-use assets	26	26	28	31	21
Other long-term assets	4	6	6	17	20
Notes receivable	6	6	0	—	—
Deferred tax assets	1	1	1	1	0
Intangible assets, net	2	2	3	75	82
Goodwill	8	7	8	7	8
Non-current assets held for sale	0	2	25	—	—
Total assets	190	203	271	349	348
Accounts payable	6	6	6	9	8
Accrued expenses and other current liabilities	16	14	14	19	18
Current liabilities held for sale	0	4	11	—	—
Total current liabilities	22	23	31	28	30
Other long-term liabilities	701,000	772,000	404,000	398,000	1
Lease liabilities	24	24	26	29	19
Non-current liabilities held for sale	0	659,000	989,000	—	—
Commitments and Contingencies	—	—	—	—	—
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024, respectively	0	0	0	0	0
Common stock, $.01 par value; 90,000 shares authorized, 15,385 issued and 13,889 outstanding and 15,010 shares issued and 14,416 outstanding at December 31, 2025 and 2024, respectively	139,000	144,000	147,000	146,000	144,000
Additional paid-in-capital	87	89	90	81	67
Accumulated other comprehensive loss	−5	−7	−6	−6	−6
Retained earnings	61	72	128	211	226
Total stockholders equity	143	154	212	286	287
Total liabilities and stockholders equity	190	203	271	349	348

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	5	7	6	7	6
Amortization of acquisition related intangible assets	357,000	1	8	8	8
Non-cash operating lease cost	2	2	2	2	2
(Gain) loss on sale of assets	−166,000	3	2	0	993,000
Loss on impairment of long-lived assets	0	2	62	—	—
Stock-based compensation expense	10	13	15	14	11
Deferred income taxes	−7,000	260,000	−6	−5	−2
Provision for doubtful accounts	265,000	1	190,000	378,000	64,000
Provision for inventory	6	45	3	5	7
Interest income on notes receivable	−896,000	0	0	—	—
Accounts receivable	408,000	3	−1	−6	−6
Inventories	30,000	−9	−11	−7	−7
Prepaid expenses, other current and long-term assets	2	558,000	560,000	−792,000	1
Accounts payable	42,000	−3	−11,000	2	−1
Operating lease liabilities	−2	−2	−2	−1	−2
Accrued expenses, other current and long-term liabilities	−2	−4	2	−443,000	4
Income taxes	−134,000	665,000	530,000	1	−1
Net cash provided by (used in) operating activities	11	5	−2	4	8
Purchases of property and equipment	−7	−8	−5	−7	−5
Proceeds from sale of Parcus	4	0	0	—	—
Notes receivable	1	0	0	—	—
Proceeds from sale of intangible assets	600,000	0	0	—	—
Acquisition of intangible assets	0	−600,000	0	0	—
Net cash used in investing activities	−401,000	−8	−5	−7	−3
Repurchases of common stock	−9	−11	−5	0	0
Proceeds from employee stock purchase program	500,000	708,000	805,000	665,000	0
Cash paid for tax withheld on vested restricted stock awards	−2	−3	−2	−934,000	−486,000
Proceeds from exercises of equity awards	0	76,000	23,000	16,000	1
Net cash used in financing activities	−11	−13	−6	−5	−7
Exchange rate impact on cash	86,000	−48,000	79,000	−130,000	69,000
Decrease in cash and cash equivalents	322,000	−16	−13	−8	−1
Cash paid for income taxes, net of refunds	1	4	3	106,000	1
Right-of-use assets obtained in exchange for operating lease liabilities	3	3	3	2	2
Purchases of property and equipment included in accounts payable and accrued expenses	666,000	639,000	815,000	108,000	15,000
Notes receivable	0	6	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Anika Therapeutics, Inc.'s CIK number?

Anika Therapeutics, Inc.'s SEC CIK number is 0000898437 (898437). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Anika Therapeutics, Inc.'s SEC filings?

All of Anika Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Anika Therapeutics, Inc. last report earnings?

Anika Therapeutics, Inc. (ANIK) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001171843-26-002799). This is Anika Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Anika Therapeutics, Inc.'s most recent earnings 8-K?

Anika Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0001171843-26-002799. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Anika Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →